X0508 4 2025-12-04 0001690585 Dianthus Therapeutics, Inc. /DE/ DNTH 0001992324 Savitz Ryan C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR NEW YORK NY 10036 false true false false CFO & CBO true Common Stock 2025-12-04 4 M false 20000 8.44 A 20000 D Common Stock 2025-12-04 4 S false 20000 45.18 D 0 D Stock Option (Right to Buy) 8.44 2025-12-04 4 M false 20000 0 A 2032-06-06 Common Stock 20000 84766 D The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. /s/ Adam Veness, as attorney-in-fact for Ryan Savitz 2025-12-05